XML 38 R24.htm IDEA: XBRL DOCUMENT
v3.19.1

SEGMENT AND ENTERPRISE-WIDE INFORMATION | 12 Months Ended
--- | ---
Mar. 30, 2019
Segment Reporting [Abstract] |
SEGMENT AND ENTERPRISE-WIDE INFORMATION | SEGMENT AND ENTERPRISE-WIDE INFORMATION The Company determines its reportable segments by first identifying its operating segments and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company's operating segments are based primarily on geography. North America Plasma is a separate operating segment with dedicated segment management due to the size and scale of the Plasma business unit. It aggregates components within an operating segment that have similar economic characteristics. The Company’s reportable segments are as follows: •Japan •EMEA •North America Plasma •All Other The Company has aggregated the Americas Blood Center and Hospital and Asia - Pacific operating segments into the All Other reportable segment based upon their similar operational and economic characteristics. The Company measures and evaluates the operating segments based on operating income. It excludes certain corporate expenses from segment operating income. In addition, certain amounts that the Company considers to be non-recurring or non-operational are excluded from segment operating income because it evaluates the operating results of the segments excluding such items. These items include restructuring and turnaround costs, deal amortization, asset impairments, PCS2 accelerated depreciation and related costs and certain legal charges. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. The Company measures and evaluates its net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis. During fiscal 2019, the Company reorganized its operating segments such that certain immaterial components of EMEA are now reported as components of All Other. Accordingly, the prior year numbers have been updated to reflect this reclassification as well as other changes within the cost reporting structure that occurred in the first quarter of fiscal 2019. These changes did not have an impact on the Company's ability to aggregate Americas Blood Center and Hospital with Asia - Pacific. Selected information by business segment is presented below:
(In thousands) | 2019 |  | 2018 |  | 2017
Net revenues |  |  |  |  |
Japan | $ | 70,227 |  |  | $ | 68,172 |  |  | $ | 74,695 |
EMEA | 169,862 |  |  | 173,551 |  |  | 188,907 |
North America Plasma | 395,922 |  |  | 333,831 |  |  | 309,718 |
All Other | 337,054 |  |  | 333,763 |  |  | 326,260 |
Net revenues before foreign exchange impact | 973,065 |  |  | 909,317 |  |  | 899,580 |
Effect of exchange rates | (5,486 | ) |  | (5,394 | ) |  | (13,464 | )
Net revenues | $ | 967,579 |  |  | $ | 903,923 |  |  | $ | 886,116 |
(In thousands) | 2019 |  | 2018 |  | 2017
Segment operating income |  |  |  |  |
Japan | $ | 36,226 |  |  | $ | 40,193 |  |  | $ | 43,042 |
EMEA | 49,730 |  |  | 68,897 |  |  | 74,878 |
North America Plasma | 167,205 |  |  | 129,697 |  |  | 109,889 |
All Other | 141,070 |  |  | 140,623 |  |  | 141,427 |
Segment operating income | 394,231 |  |  | 379,410 |  |  | 369,236 |
Corporate operating expenses | (237,568 | ) |  | (252,222 | ) |  | (249,048 | )
Effect of exchange rates | 8,367 |  |  | 4,059 |  |  | (4,772 | )
Restructuring and turnaround costs | (13,660 | ) |  | (44,125 | ) |  | (34,337 | )
Deal amortization | (24,803 | ) |  | (26,013 | ) |  | (27,107 | )
Impairment of assets | (21,170 | ) |  | (1,941 | ) |  | (73,353 | )
Legal charges | (2,726 | ) |  | (3,011 | ) |  | — |
PCS2 accelerated depreciation and related costs | (19,126 | ) |  | — |  |  | — |
Operating income (loss) | $ | 83,545 |  |  | $ | 56,157 |  |  | $ | (19,381 | )
(In thousands) | 2019 |  | 2018 |  | 2017
Depreciation and amortization |  |  |  |  |
Japan | $ | 520 |  |  | $ | 486 |  |  | $ | 827 |
EMEA | 4,153 |  |  | 4,464 |  |  | 4,255 |
North America Plasma | 39,497 |  |  | 16,060 |  |  | 13,022 |
All Other | 65,248 |  |  | 68,237 |  |  | 71,629 |
Total depreciation and amortization (excluding impairment charges) | $ | 109,418 |  |  | $ | 89,247 |  |  | $ | 89,733 |
(In thousands) | March 30, 2019 |  | March 31, 2018 |  | April 1, 2017
Long-lived assets(1) |  |  |  |  |
Japan | $ | 26,660 |  |  | $ | 26,640 |  |  | $ | 21,412 |
EMEA | 71,048 |  |  | 74,783 |  |  | 63,854 |
North America Plasma | 113,921 |  |  | 91,815 |  |  | 142,164 |
All Other | 132,350 |  |  | 138,918 |  |  | 96,432 |
Total long-lived assets | $ | 343,979 |  |  | $ | 332,156 |  |  | $ | 323,862 |
(1) Long-lived assets are comprised of property, plant and equipment.
Selected information by principle operating regions is presented below:
(In thousands) | 2019 |  | 2018 |  | 2017
Net Revenues |  |  |  |  |
United States | $ | 606,845 |  |  | $ | 548,731 |  |  | $ | 522,686 |
Japan | 69,908 |  |  | 67,319 |  |  | 79,266 |
Europe | 164,504 |  |  | 164,226 |  |  | 166,007 |
Asia | 118,700 |  |  | 115,127 |  |  | 109,858 |
Other | 7,622 |  |  | 8,520 |  |  | 8,299 |
Net revenues | $ | 967,579 |  |  | $ | 903,923 |  |  | $ | 886,116 |
(In thousands) | March 30, 2019 |  | March 31, 2018 |  | April 1, 2017
Long-lived assets(1) |  |  |  |  |
United States | $ | 269,849 |  |  | $ | 236,603 |  |  | $ | 241,610 |
Japan | 1,726 |  |  | 1,511 |  |  | 1,691 |
Europe | 11,200 |  |  | 13,696 |  |  | 12,952 |
Asia | 30,930 |  |  | 36,431 |  |  | 34,174 |
Other | 30,274 |  |  | 43,915 |  |  | 33,435 |
Total long-lived assets | $ | 343,979 |  |  | $ | 332,156 |  |  | $ | 323,862 |
(1) Long-lived assets are comprised of property, plant and equipment.
The Company's products are organized into three categories for purposes of evaluating their growth potential: Plasma, Blood Center and Hospital. Management reviews revenue trends based on these business units. Net revenues by business unit are as follows:
(In thousands) | 2019 |  | 2018 |  | 2017
Plasma | 501,837 |  |  | 435,956 |  |  | 410,727 |
Blood Center | 269,203 |  |  | 284,902 |  |  | 303,890 |
Hospital | 196,539 |  |  | 183,065 |  |  | 171,499 |
Net revenues | $ | 967,579 |  |  | $ | 903,923 |  |  | $ | 886,116 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration